| USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation S Ling, Q Shan, Q Zhan, Q Ye, P Liu, S Xu, X He, J Ma, J Xiang, G Jiang, ... Gut 69 (7), 1322-1334, 2020 | 138 | 2020 |
| Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle … L Xu, S Xu, H Wang, J Zhang, Z Chen, L Pan, J Wang, X Wei, H Xie, ... ACS applied materials & interfaces 10 (4), 3229-3240, 2018 | 49 | 2018 |
| Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity H Wang, J Wu, L Xu, K Xie, C Chen, Y Dong Chemical Communications 53 (17), 2618-2621, 2017 | 42 | 2017 |
| Gefitinib synergizes with irinotecan to suppress hepatocellular carcinoma via antagonizing Rad51-mediated DNA-repair J Shao, Z Xu, X Peng, M Chen, Y Zhu, L Xu, H Zhu, B Yang, P Luo, Q He PLoS One 11 (1), e0146968, 2016 | 34 | 2016 |
| Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1 L Xu, Y Zhu, J Shao, M Chen, H Yan, G Li, Y Zhu, Z Xu, B Yang, P Luo, ... British journal of cancer 116 (8), 1027-1036, 2017 | 27 | 2017 |
| A facile supramolecular approach to fabricate multifunctional upconversion nanoparticles as a versatile platform for drug loading, in vivo delivery and tumor imaging Y Yuan, L Xu, S Dai, M Wang, H Wang Journal of Materials Chemistry B 5 (13), 2425-2435, 2017 | 27 | 2017 |
| The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis C Zhang, K Chen, R Wei, G Fan, X Cai, L Xu, B Cen, J Wang, H Xie, ... Signal transduction and targeted therapy 5 (1), 23, 2020 | 22 | 2020 |
| The role of transcription factor 7‐like 2 in metabolic disorders Z Zhang, L Xu, X Xu Obesity Reviews 22 (5), e13166, 2021 | 20 | 2021 |
| NEAT1/hsa-miR-372–3p axis participates in rapaMYCin-induced lipid metabolic disorder G Fan, C Zhang, X Wei, R Wei, Z Qi, K Chen, X Cai, L Xu, L Tang, J Zhou, ... Free Radical Biology and Medicine 167, 1-11, 2021 | 11 | 2021 |
| Multi-omics profiling reveals Chitinase-3-like protein 1 as a key mediator in the crosstalk between sarcopenia and liver cancer D Lu, Z Lin, R Wang, Z Chen, J Zhuo, L Xu, L Pan, H Li, X Yang, C He, ... Redox Biology 58, 102538, 2022 | 10 | 2022 |
| “Sweet tooth”-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy N Ding, S Xu, S Zheng, Q Ye, L Xu, S Ling, S Xie, W Chen, Z Zhang, ... Journal of Materials Chemistry B 9 (12), 2816-2830, 2021 | 10 | 2021 |
| Delivery of microRNA-33 antagomirs by mesoporous silica nanoparticles to ameliorate lipid metabolic disorders Y Tao, S Xu, J Wang, L Xu, C Zhang, K Chen, Z Lian, J Zhou, H Xie, ... Frontiers in Pharmacology 11, 921, 2020 | 10 | 2020 |
| CT radiomics for noninvasively predicting NQO1 expression levels in hepatocellular carcinoma Z He, X Shen, B Wang, L Xu, Q Ling Plos one 18 (9), e0290900, 2023 | 1 | 2023 |
| Fibroblast growth factor 21 (FGF21) attenuates tacrolimus-induced hepatic lipid accumulation through transcription factor EB (TFEB)-regulated lipophagy Z Zhang, L Xu, X Qiu, X Yang, Z Lian, X Wei, D Lu, X Xu Journal of Zhejiang University-SCIENCE B 24 (6), 485-495, 2023 | 1 | 2023 |
| SN-38 与索拉非尼联合应用体外抗肝癌效果及其机制 XU Li, Y ZHU, C Jian, X YANG, P LUO Journal of Zhejiang University (Medical Sciences) 44 (5), 486, 2015 | | 2015 |
Xiao XuZhejiang University在 zju.edu.cn 的电子邮件经过验证
Xiao XuZhejiang University在 zju.edu.cn 的电子邮件经过验证
Hangxiang WangThe First Affiliated Hospital, Zhejiang University School of Medicine在 zju.edu.cn 的电子邮件经过验证